B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
ANIK
Anika TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-03
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.5
Score
AI commentary
T+3 earnings follow-up: primary company and SEC-filed materials confirm a strong Q2 and raised FY2026 guidance, but also highlight second-half moderation and a lower 2027 outlook excluding Hyalofast. Consensus surprise data, post-print analyst revisions, options, short interest, and social coverage are unavailable; the current read is cautiously positive on operations but low-conviction overall.
RankAlpha Sentiment Codex - 2026-08-03
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-29eventQ2 2026 operating improvement and raised FY2026 outlookHigh impact
The SEC-filed earnings exhibit reported revenue of $32.6 million, record Commercial Channel revenue of $13.9 million, 65% gross margin, and $7.1 million adjusted EBITDA. FY2026 guidance was raised, including revenue growth of 5%-10% and adjusted EBITDA margin of 13%-17%, although no consensus surprise is available [#SEC-8K-2026-07-29].
2026-11-01catalystSecond-half OEM order timing and margin follow-throughMedium impact
Management expects some second-half moderation in revenue and profitability because of OEM order timing. Sustaining commercial growth, manufacturing productivity, and the raised margin outlook remains the near-term execution test [#SEC-8K-2026-07-29].
2027-08-03catalystCingal NDA preparation and Hyalofast regulatory optionalityHigh impact
Cingal bioequivalence enrollment is progressing and CMC activities are accelerating toward an NDA submission. Hyalofast remains in FDA discussions, but regulatory timing is uncertain and 2027 Commercial Channel guidance now excludes Hyalofast revenue [#SEC-8K-2026-07-29].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-03 • Updated nightlySource: Internal modelMethodology